Literature DB >> 23852892

Downregulation of CD24 inhibits invasive growth, facilitates apoptosis and enhances chemosensitivity in gastric cancer AGS cells.

X-L Jiao1, C Zhao, M Niu, D Chen.   

Abstract

BACKGROUND AND AIM: The human CD24 antigen is a small heavily glycosylated cell surface protein, which is expressed in a large variety of solid tumors,including gastric cancer. Enriched on the surface of many tumor cells,CD24 promotes tumor growth,invasion and metastasis and confers resistance to some chemotherapeutic drugs.In this study, we investigated the possible effect of CD24 suppression on proliferation, apoptosis, migration, invasion and chemosensitivity of gastric cancer (GC) cells.
MATERIALS AND METHODS: We down-regulated CD24 expression by RNA interference and investigated the effects on proliferation, apoptosis, chemosensitivity to doxorubicin, malignant and metastatic potential of a human gastric cancer cell line, AGS, CD24-suppressed clones, AGS-CD24-siRNA-C2, AGS-CD24-siRNA-C4 and AGS-CD24-siRNA-C5 in vitro. We evaluated the effects of CD24 suppression in vivo on xenograft tumor growth and metastatic properties following tail iv AGS-CD24-siRNA-C2, AGS-CD24-siRNA-C4 and AGS-CD24-siRNA-C5 clones. We also investigated the effect of CD24-siRNA followed by doxorubicin administration treatment on the xenograft tumor growth.
RESULTS: CD24 suppressed showed significantly decreased proliferation, invasion and increased apoptosis as well as increased chemosensitivity to doxorubicin in vitro and in vivo.
CONCLUSIONS: CD24 involves in proliferation, invasion and chemosensitivity of human gastric cancer cell line AGS, and that down-regulation of CD24 protein expression decreases the metastatic potential and increases chemosensitivity of gastric cancer (GC) cells. Thus, CD24 may be a promising therapeutic target for gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23852892

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

Review 1.  Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance.

Authors:  Sruthi Sritharan; Sampurna Guha; Snoopy Hazarika; Nageswaran Sivalingam
Journal:  Apoptosis       Date:  2022-06-18       Impact factor: 5.561

2.  Lrg participates in lipopolysaccharide preconditioning-induced brain ischemia injury via TLR4 signaling pathway.

Authors:  Gu Gong; Shurong Bai; Wei Wu; Ling Hu; Yinghai Liu; Jie Niu; Xuemei Dai; Liang Yin; Xiaowu Wang
Journal:  J Mol Neurosci       Date:  2014-02-15       Impact factor: 3.444

3.  Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.

Authors:  Yanping Chen; Jinlian Song; Yuhong Jiang; Chundong Yu; Zhongliang Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis.

Authors:  Jason E Duex; Charles Owens; Ana Chauca-Diaz; Garrett M Dancik; Lauren A Vanderlinden; Debashis Ghosh; Mariah Z Leivo; Donna E Hansel; Dan Theodorescu
Journal:  Cancer Res       Date:  2017-07-03       Impact factor: 12.701

5.  High Expression Level of PPARγ in CD24 Knockout Mice and Gender-Specific Metabolic Changes: A Model of Insulin-Sensitive Obesity.

Authors:  Shiran Shapira; Dina Kazanov; Rachel Dankner; Sigal Fishman; Naftali Stern; Nadir Arber
Journal:  J Pers Med       Date:  2021-01-15

Review 6.  A promising antitumor method: Targeting CSC with immune cells modified with CAR.

Authors:  Binjie Huang; Lele Miao; Jie Liu; Jiaxing Zhang; Yumin Li
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

Review 7.  Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.

Authors:  Lia Walcher; Ann-Kathrin Kistenmacher; Huizhen Suo; Reni Kitte; Sarah Dluczek; Alexander Strauß; André-René Blaudszun; Tetyana Yevsa; Stephan Fricke; Uta Kossatz-Boehlert
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.